Drugs / PPV-06
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04447898 | Feb 2021 → Feb 2023 | osteoarthritis, knee | Peptinov SAS | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06605963 | Dec 2025 → Dec 2028 expected | osteoarthritis, knee | Peptinov SAS | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPV-06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06605963 ↗ |
| Action | Inhibit | “The antibodies produced will neutralize the biological activity of IL-6 involved in the body's inflammatory process.” NCT04447898 ↗ |
| Modality | Vaccine | “vaccination with PPV-06” NCT04447898 ↗ |
| Route | Subcutaneous | “in SC administration” NCT04447898 ↗ |
| Target | IL6 | “PPV-06 immunotherapy targets interleukin-6 (IL-6)” NCT04447898 ↗ |